A detailed history of Squarepoint Ops LLC transactions in An2 Therapeutics, Inc. stock. As of the latest transaction made, Squarepoint Ops LLC holds 64,267 shares of ANTX stock, worth $73,264. This represents 0.0% of its overall portfolio holdings.

Number of Shares
64,267
Previous 10,062 538.71%
Holding current value
$73,264
Previous $10,000 710.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

BUY
$1.05 - $1.34 $56,915 - $72,634
54,205 Added 538.71%
64,267 $81,000
Q2 2025

Aug 14, 2025

BUY
$1.06 - $1.4 $10,665 - $14,086
10,062 New
10,062 $10,000
Q4 2024

Feb 14, 2025

BUY
$1.0 - $1.67 $62,441 - $104,276
62,441 New
62,441 $84,000
Q2 2024

Aug 14, 2024

BUY
$1.93 - $3.76 $91,590 - $178,434
47,456 Added 95.66%
97,063 $208,000
Q1 2024

May 15, 2024

BUY
$2.78 - $21.53 $137,907 - $1.07 Million
49,607 New
49,607 $161,000

Others Institutions Holding ANTX

About AN2 Therapeutics, Inc.


  • Ticker ANTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 19,402,700
  • Market Cap $22.1M
  • Description
  • AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...
More about ANTX
Track This Portfolio

Track Squarepoint Ops LLC Portfolio

Follow Squarepoint Ops LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.